UnknownNot Applicable

The Effect of BRIZO on Lower Urinary Tract Symptoms (LUTS) Related to Benign Prostatic Hypertrophy (BPH)

Israel120 participantsStarted 2022-08

Plain-language summary

A randomized, placebo controlled double-blind, 12-week treatment trial in men with moderate to severe symptoms of benign prostatic hyperplasia. The trail is about to examine the effect of Brizo® on reduction of BPH related symptoms.

Who can participate

Age range50 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Males in good general health at least 50 years of age, with symptoms of moderate to severe benign prostatic hyperplasia Exclusion Criteria: * Inability to complete the questionnaire. * Patients with or suspected of having prostate cancer. * Patients who have undergone a surgical procedure in the past year and / or who have taken medications or supplements in the past six months to treat BPH. * Patients treated with drugs for kidney / urinary tract problems. * Allergy to soy.

What they're measuring

Improved index in the IPSS test

Timeframe: 12 weeks

Trial details

NCT IDNCT05227508

SponsorSe-cure Pharmaceuticals Ltd.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2024-01

Contact for this trial

Ohad Shoshani, MD

+972-54-9577567 ohadsh10@gmail.com

View on ClinicalTrials.gov More BPH Without Urinary Obstruction and Other Lower Urinary Tract Symptoms (LUTS) trials